FDA
-
Lilly cancer drug cleared by FDA for expanded leukemia, lymphoma use
Jaypirca, which has been on the market for less than a year, can now be used for more types of blood cancer but not as early as rival drugs from AbbVie and AstraZeneca.
By Jonathan Gardner • Dec. 4, 2023 -
shutterstock.com/DadBusiness
Sponsored by Target RWEOvercoming scalability challenges in real-world data processing for transformative patient care
Accurate and timely processing of data is imperative to create robust analytical datasets that can be used in the RWE setting.
By Rob Sullivan, Chief Data & Analytics Officer • Dec. 4, 2023 -
Jacob Bell
FDA names chief scientist Bumpus as Woodcock’s successor
Bumpus, a former Johns Hopkins professor, named “creating a new model” for the FDA’s Office of Regulatory Affairs as one of her priorities when she steps into the role next year.
By Jonathan Gardner • Nov. 29, 2023 -
Peddalanka Ramesh Babu via Getty Images
FDA investigating cancer risk linked to CAR-T cell therapy
Reports of T cell malignancies following treatment triggered the FDA’s alert. But the event appears rare, according to companies and physicians.
By Jonathan Gardner • Updated Nov. 28, 2023 -
Win McNamee via Getty Images
Top FDA official Woodcock to retire early next year
The 37-year veteran helmed the agency’s pandemic response, and was a key decision-maker in controversial calls on opioids, an Alzheimer's therapy and muscular dystrophy drugs.
By Jonathan Gardner • Updated Nov. 17, 2023 -
SciePro via Getty Images
FDA approves new Bristol Myers drug for lung cancer
Acquired via a $4 billion biotech buyout, Augtyro is one of an array of new products the pharma hopes will offset patent expirations for current top sellers.
By Jonathan Gardner • Nov. 16, 2023 -
Valneva’s chikungunya vaccine approved by FDA
The preventive shot is the first to receive regulatory approval for the mosquito-borne illness, which is growing in prevalence worldwide.
By Delilah Alvarado • Nov. 10, 2023 -
Jacob Bell
Takeda secures FDA approval for colon cancer drug
The pharma paid $400 million to license the drug from Hutchmed earlier this year in an effort to bolster its oncology business.
By Delilah Alvarado • Nov. 9, 2023 -
Sarah Silbiger via Getty Images
Obesity drugsLilly rival to weight loss drug Wegovy approved by FDA
The pharmaceutical company will sell the GLP-1 drug, branded as Zepbound, at a list price about 20% lower than Novo Nordisk's competing therapy.
By Jonathan Gardner , Ned Pagliarulo • Updated Nov. 8, 2023 -
Sarah Silbiger via Getty Images
Vertex, CRISPR therapy for sickle cell passes FDA panel test
The high-profile meeting focused on the theoretical risks of CRISPR gene editing, as both the FDA and its advisory committee appeared convinced by the efficacy of the companies’ exa-cel treatment.
By Ned Pagliarulo • Oct. 31, 2023 -
A play-by-play of the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy
Expert advisers dug deep on the risks of off-target gene editing and debated how best to set guidelines for the fast-growing field. Catch up on their full discussion here.
By Ned Pagliarulo , Jonathan Gardner , Gwendolyn Wu • Updated Oct. 31, 2023 -
Sarah Silbiger/Getty Images via Getty Images
Gene editingFDA staff focus on ‘off-target’ risk in review of Vertex, CRISPR sickle cell therapy
Documents released ahead of a Tuesday advisory meeting show agency scientists to be generally convinced by the treatment’s benefit, a sign analysts read as positive.
By Ned Pagliarulo • Oct. 27, 2023 -
Permission granted by AstraZeneca
Supply shortage hits infant RSV antibody Beyfortus
The CDC is asking doctors to ration supply of Sanofi and AstraZeneca’s new RSV drug Beyfortus, as demand has outstripped supply.
By Delilah Alvarado • Oct. 25, 2023 -
Novartis
Novartis delays FDA filing for in-demand radiopharma drug
Mixed survival data from a study of Pluvicto in earlier prostate cancer sparked the slower regulatory timeline.
By Jonathan Gardner • Oct. 24, 2023 -
Jeenah Moon via Getty Images
Pfizer wins FDA approval of new meningococcal vaccine
The clearance of the pentavalent shot Penbraya adds to Pfizer’s infectious disease portfolio as it adjusts to slumping COVID-19 vaccine sales.
By Delilah Alvarado • Oct. 23, 2023 -
Sarah Silbiger via Getty Images
ALS drug developmentBrainStorm, after setbacks, withdraws approval application for ALS drug
A panel of FDA advisers last month found BrainStorm’s data unconvincing. The company now says a Phase 3b study will be needed for its NurOwn cell therapy to have a shot at an approval.
By Jacob Bell • Oct. 18, 2023 -
Courtesy of Merck & Co.
Keytruda gains first approval for pre- and post-surgery use in lung cancer
The Merck drug leads competitors Opdivo and Imfinzi into a new immunotherapy setting, which aims to improve outcomes following the surgical removal of tumors.
By Jonathan Gardner • Oct. 17, 2023 -
Erik Karits via Getty Images
Research group says FDA found no misconduct in Pfizer Lyme vaccine trial it helped run
Earlier this year Pfizer removed thousands of participants from a study of its Lyme disease shot over concerns the group, Care Access, wasn't meeting clinical practice standards.
By Delilah Alvarado • Oct. 12, 2023 -
Sarah Silbiger via Getty Images
PepGen cleared by FDA to begin study of muscular dystrophy drug
The company expects to deliver first results next year from the early-stage study of people with myotonic dystrophy type 1.
By Kristin Jensen • Oct. 12, 2023 -
Alnylam Pharmaceuticals
FDA denies expanded approval for Alnylam RNA drug
The agency rejected Alnylam’s application for approval of its medicine patisiran in people with a rare heart condition, setting back the company’s plans.
By Jonathan Gardner • Updated Oct. 9, 2023 -
Sarah Silbiger via Getty Images
FDA panel finds KRAS drug data unreliable, in blow to Amgen
The negative panel vote likely means Amgen will need more data to support a full approval for its conditionally cleared lung cancer drug Lumakras.
By Ned Pagliarulo • Updated Oct. 6, 2023 -
Sarah Silbiger via Getty Images
5 FDA decisions to watch in the fourth quarter
The regulator’s decision on Alnylam’s bid to expand Onpattro’s approval didn’t go the company’s way, but other verdicts await on drugs from Vertex, Bristol Myers, Amgen and Pfizer.
By Ned Pagliarulo , Jonathan Gardner • Oct. 2, 2023 -
Sarah Silbiger via Getty Images
ALS drug developmentBrainStorm’s ALS therapy not effective, FDA panel finds
Expert advisers to the agency voted 17-1 that Brainstorm's clinical trial data did not show the company's stem cell treatment to be effective for treating ALS.
By Ned Pagliarulo • Updated Sept. 28, 2023 -
Courtesy of U.S. Food and Drug Administration
ALS drug developmentFDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show
A panel of expert FDA advisers is meeting today to discuss the treatment, and whether Brainstorm’s data provide “substantial evidence” of its effectiveness.
By Ned Pagliarulo • Sept. 25, 2023 -
Sarah Silbiger via Getty Images
Intarcia’s diabetes drug-device combo voted down again by FDA panel
The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.
By Gwendolyn Wu • Sept. 21, 2023
